The Personnalized Medicine Coalition (PMC) brings together innovators, scientists, patients, providers and payers, to promote the understanding and adoption of personalised medicine concepts, services, and products to benefit patients and the health system. This international and multistakeholder organization also supports investment in and adoption of personalized medicine through education, advocacy, and evidence development.
The infrastructure’s joining forces with PMC demonstrates EATRIS community’s growing commitment to actively contribute to the evolving field of personalised medicine and the leading role played by translational research approach to make personalised medicine a reality for patients and health systems around the world.
As a member, EATRIS will have the opportunity to raise the voice of the European translational community in shaping the future strategic agenda of the Coalition, will participate in joint education and advocacy activities to raise the profile and scope of personalised medicine, and engage with regulators and other policymakers. The current members of the coalition also include representatives from patient advocacy groups, venture capital, pharmaceutical companies, and diagnostic companies, among others.